Who
Joseph C. Papa
Director
Company insider
Files Form 4 as: Director, Candel Therapeutics; Director, Milestone Pharmaceuticals; President and CEO, Emergent BioSolutions; Director, Prometheus Biosciences; Chairman & CEO, Bausch Health Companies; CEO & Chairman, Bausch + Lomb; CEO, Perrigo Company; President and CEO, Perrigo Co.
In numbers
- Trades disclosed
- 373
- Buys
- 9
- Sells
- 38
- Bought
- $8.2M
- Sold
- $43.2M
- Companies
- 8
- Companies where not an officer
- 4
- First trade
- 9 Oct 2006
- Last trade
- 30 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 2 Oct 2026 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $11K1,325 at $8.68 | filing |
| 30 Jun 2026filed 1 Jul 2026 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $11K1,331 at $8.64 | filing |
| 30 Jun 2026filed 1 Jul 2026 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $11K1,331 at $8.64 | filing |
| 23 Jun 2026filed 24 Jun 2026 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 23 Jun 2026filed 24 Jun 2026 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,000 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —187,708 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —187,708 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $11K2,795 at $4.11 | filing |
| 31 Mar 2026filed 2 Apr 2026 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $11K2,795 at $4.11 | filing |
| 5 Mar 2026filed 5 Mar 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $313K37,055 at $8.44 | filing |
| 5 Mar 2026filed 5 Mar 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $313K37,055 at $8.44 | filing |
| 3 Mar 2026filed 5 Mar 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —252,194 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —252,194 at $0.00 | filing |
| 11 Jul 2025filed 15 Jul 2025 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 | filing |
| 11 Jul 2025filed 15 Jul 2025 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 | filing |
| 11 Jul 2025filed 15 Jul 2025 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —100,000 | filing |
| 25 Jun 2025filed 26 Jun 2025 | CADL Candel TherapeuticsBiotechnology | SEC FORM 4 Code A | $300K64,239 at $4.67 | filing |
| 17 Jun 2025filed 18 Jun 2025 | CADL Candel Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,240 at $0.00 | filing |
News
Ovid Therapeutics (NASDAQ:OVID) and Perrigo (NYSE:PRGO) Head to Head ReviewPRGO · themarketsdaily.com · 20 Oct 2026Comparing Monte Rosa Therapeutics (NASDAQ:GLUE) and Emergent Biosolutions (NYSE:EBS)EBS · tickerreport.com · 16 Oct 2026Contrasting Ocular Therapeutix (NASDAQ:OCUL) and Bausch Health Cos (NYSE:BHC)BHC · dailypolitical.com · 13 Oct 2026Contrasting Neurocrine Biosciences (NASDAQ:NBIX) and Perrigo (NYSE:PRGO)PRGO · dailypolitical.com · 10 Oct 2026Contrasting Bausch Health Cos (NYSE:BHC) and Journey Medical (NASDAQ:DERM)BHC · themarketsdaily.com · 8 Oct 2026
0 headlines in the last 90 days name Joseph C. Papa; 5 articles from the last 14 days about the 4 companies they traded most, at most three about any one of them.